Care for diabetes with COVID‐19: Advice from China

作者：Weiqing Wang, Jieli Lu, Weiqiong Gu, Yifei Zhang, Jianmin Liu, Guang Ning · 发表于：Journal of Diabetes · 年份：2020 · DOI：10.1111/1753-0407.13036 · 被引用次数：61 · 研究领域：COVID-19 Clinical Research Studies、Diabetes and associated disorders、Diabetes Management and Research

The epidemic of the coronavirus disease 2019 (COVID-19) has expanded from Wuhan throughout China and is being exported to a growing number of countries outside of China.1 The growing epidemic of COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).2 The potential public health threat posed by COVID-19 is very high, both to China and globally. By 9 March 2020, 80 904 cases of COVID-19, including more than 3123 deaths, had been confirmed in China, mainly in Hubei province.3 A further 28 673 laboratory confirmed cases have been reported across 104 other countries/territories/areas.3 Considering the high proportion of critically ill patients with diabetes or hyperglycemia, the difficulty for treatment and high mortality rate, effective diabetes management under epidemic conditions is extremely important. In order to increase disease awareness and improve the prognosis and outcome of patients with diabetes, better understanding of the etiological associations between COVID-19 and diabetes, the clinical impact of COVID-19 on diabetes, and proposing detailed recommendations for prevention and treatment are needed.4, 5 Epidemiologic evidences suggest that diabetes is associated with high risk of infectious diseases. People with diabetes are at increased risk for the bacteremic form of pneumococcal infection and have been reported to have a high risk of nosocomial bacteremia, with a mortality rate as high as 50%.6 In the nationwide China Cardiometabol...